The Experts below are selected from a list of 294 Experts worldwide ranked by ideXlab platform
Jost B. Jonas - One of the best experts on this subject based on the ideXlab platform.
-
intraocular concentration of Triamcinolone acetonide after intravitreal injection in the rabbit eye
Ophthalmology, 2008Co-Authors: Bernd A Kamppeter, Ali Cej, Jost B. JonasAbstract:Purpose To examine the decrease in the intraocular concentration of intravitreally injected Triamcinolone acetonide over an 8-month period in a rabbit model. Design Experimental study. Participants The study included 18 white New Zealand rabbits. Methods The animals received an intravitreal injection of 6 mg Triamcinolone acetonide. Vitreous and aqueous humor samples of the anterior and posterior chamber were taken at the first and third day, at 1 and 2 weeks, and at 1, 1.5, 2, 3, 6, and 8 months. The concentrations of Triamcinolone were analyzed using a high-phase liquid chromatography assay. Main Outcome Measures Intraocular concentration of Triamcinolone during follow-up. Results Over the entire study period, Triamcinolone concentrations were significantly higher in the vitreous samples than in the anterior chamber samples (day 1, 14 434±10 768 μg/l vs. 21.0±18.9 μg/l; day 30, 571.3±329.6 μg/l vs. 6.1±1.6 μg/l; month 8, 70.7±37.0 μg/l vs. 3.3±1.6 μg/l). In the anterior chamber, the Triamcinolone concentrations were highest at 3 days after the injection (28.9±24.5 μg/l), and in the vitreous, the concentrations were highest at the first day (14,434.0±10,768 μg/l). Triamcinolone levels in the vitreous and in the anterior chamber followed a 2-compartment model, with an exponential decrease in the concentration within the first 4 weeks, followed by a steady decline over the following months. At 8 months, the Triamcinolone concentrations were 70.7±37.0 μg/l in the vitreous samples and 3.3±1.6 μg/l in the anterior chamber samples. Conclusions The decrease in the concentration of Triamcinolone after an intravitreal injection of 6 mg in rabbits follows a 2-compartment model, with an exponential decrease in the first 4 weeks followed by a more linear decrease. During the entire study period, the Triamcinolone concentration was significantly higher in the vitreous than in the anterior chamber. After a single intravitreal Triamcinolone injection of 6 mg in rabbits, Triamcinolone is detectable for at least 8 months after the injection.
-
intraocular pressure elevation after intravitreal Triamcinolone acetonide injection
Ophthalmology, 2005Co-Authors: Jost B. Jonas, Ingrid Kreissig, Robert F. Degenring, Imren Akkoyun, Bernd A KamppeterAbstract:Purpose To report on intraocular pressure (IOP) after intravitreal injections of Triamcinolone acetonide. Design Meta-analysis of previously reported data and case series studies. Participants The study included 272 patients (305 eyes) receiving an intravitreal injection of approximately 20 mg Triamcinolone acetonide as treatment for diffuse diabetic macular edema (n = 84 patients), exudative age-related macular degeneration (n = 181 patients), retinal vein occlusions (n = 20 patients), uveitis (n = 9), pseudophakic cystoid macular edema (n = 6), and other reasons (n = 5). Mean follow-up was 10.4±6.7 months (median, 7.9 months; range, 3.0–35.7 months). Intervention Intravitreal injection of approximately 20 mg Triamcinolone acetonide. Main Outcome Measure Intraocular pressure. Results Intraocular pressure readings higher than 21 mmHg, 30 mmHg, 35 mmHg, and 40 mmHg, respectively, were measured in 112 (41.2%) patients, 31 (11.4%) patients, 15 (5.5%) patients, and 5 (1.8%) patients, respectively. Triamcinolone-induced IOP elevation was treated by antiglaucoma medication in all but 3 (1.0%) eyes, for which filtering surgery was performed. Mean IOP started to rise 1 week after injection and returned to baseline values approximately 8 to 9 months after injection. Younger age ( P = 0.029) was significantly associated with Triamcinolone-induced ocular hypertension. Triamcinolone responders and Triamcinolone nonresponders did not vary significantly in gender ( P = 0.42), refractive error ( P = 0.86), diabetes mellitus status ( P = 0.74), and reason for treatment. Conclusions These findings may be useful for comparing risks and benefits of intravitreal Triamcinolone acetonide therapy.
-
Triamcinolone acetonide concentration after filtration of the solvent agent
American journal of ophthalmology, 2005Co-Authors: Ulrich H. M. Spandau, Mathias Derse, Paul Schmitz-valckenberg, Christos Papoulis, Bernd-udo Sagstetter, Karlheinz Stiefvater, Jost B. JonasAbstract:Purpose To determine the amount of Triamcinolone acetonide and the preservative benzyl alcohol after filtration. Design Laboratory investigation. Methods The probes were prepared by two different hospital pharmacies. The probes of the first pharmacy included 20 probes with 25-mg Triamcinolone acetonide, unfiltered (n = 5 probes) or filtered (n = 5), or with 4-mg Triamcinolone acetonide, filtered (n = 5) or unfiltered (n = 5). The probes for the second pharmacy were filtered (n = 3) probes of 25-mg Triamcinolone acetonide. Results For the probes of the first pharmacy, Triamcinolone acetonide dosages were 2.4 ± 0.8 mg, 3.1 ± 0.6 mg, 12.8 ± 0.7 mg, and 23.4 ± 2.3 mg, respectively, for the filtered 4-mg probes, unfiltered 4-mg probes, filtered 25-mg probes, and unfiltered 25-mg probes, respectively. For the second pharmacy, mean Triamcinolone acetonide dosage was 23.8 ± 0.6 mg for the 25-mg filtered probes and contained benzyl alcohol in a mean concentration of 0.0013 ± 0.0001 mg/0.1 ml Conclusions Depending on the method employed and the pharmacy, preparation of Triamcinolone acetonide including filtration of the solvent agent leads to a marked inter-pharmacy variation and a relatively low intra-pharmacy variation in the reduction of Triamcinolone acetonide dosage.
-
Serum levels of Triamcinolone acetonide after intravitreal injection
American journal of ophthalmology, 2004Co-Authors: Robert F. Degenring, Jost B. JonasAbstract:Abstract Purpose To evaluate serum levels of Triamcinolone acetonide after intravitreal high-dose injection. Design Prospective, interventional case series study. Methods For 20 consecutive patients, venous blood samples were taken before and 13 ± 19 days (range 4 to 92) after an intravitreal injection of 20 to 25 mg Triamcinolone acetonide as treatment of edematous macular diseases. Results Serum levels of Triamcinolone acetonide did not differ significantly ( P = .174; t test for paired matches) preoperatively (0 μg/l) and postoperatively (0.065 μg/l ± 0.21 μg/l). In 18 eyes (90%), Triamcinolone acetonide could not be detected in serum samples. For two patients (10%), serum samples taken 5 days and 7 days after the injection, respectively, contained 0.5 μg/l Triamcinolone acetonide and 0.8 μg/l Triamcinolone acetonide, respectively. Conclusion After an intravitreal high-dose injection of 20 to 25 mg Triamcinolone acetonide, Triamcinolone acetonide is not, or only marginally, detectable in serum samples obtained within 4 to 92 days after the injection.
Rolf Karlicek - One of the best experts on this subject based on the ideXlab platform.
-
reversed phase porous silica rods an alternative approach to high performance liquid chromatographic separation using the sequential injection chromatography technique
Journal of Chromatography A, 2003Co-Authors: Dalibor Satinský, Petr Solich, Jitka Huclova, Rolf KarlicekAbstract:Abstract A commercially available porous silica rod column was used as a separation tool for the sequential injection analysis (SIA). A porous solid monolithic column showed high performance at a low pressure, allowing sequential injection analysis to be used for the first time for separation in HPLC fashion. In this contribution, we tried to demonstrate a new separation concept with SIA manifold for the simultaneous determination of four different compounds (methylparaben (MP), propylparaben (PP), Triamcinolone acetonide (TCA) and internal standard ketoprofen (KP)) in a pharmaceutical triamcinolon cream 0.1% formulation. A Chromolith Flash RP-18e, 25 mm ×4.6 mm column with a 10 mm pre-column (Merck, Germany) and a FIAlab 3000 system (USA) with an 8-port selection valve and 10 ml syringe were used for sequential injection chromatographic separations in our study. The mobile phase used was acetonitrile–methanol–water (35:5:65, v/v/v) + 0.05% nonylamine, pH 2.5, flow rate 0.6 ml min−1. The analysis time was
-
reversed phase porous silica rods an alternative approach to high performance liquid chromatographic separation using the sequential injection chromatography technique
Journal of Chromatography A, 2003Co-Authors: Dalibor Satinský, Petr Solich, Jitka Huclova, Rolf KarlicekAbstract:A commercially available porous silica rod column was used as a separation tool for the sequential injection analysis (SIA). A porous solid monolithic column showed high performance at a low pressure, allowing sequential injection analysis to be used for the first time for separation in HPLC fashion. In this contribution, we tried to demonstrate a new separation concept with SIA manifold for the simultaneous determination of four different compounds (methylparaben (MP), propylparaben (PP), Triamcinolone acetonide (TCA) and internal standard ketoprofen (KP)) in a pharmaceutical triamcinolon cream 0.1% formulation. A Chromolith Flash RP-18e, 25 mm x 4.6 mm column with a 10 mm pre-column (Merck, Germany) and a FIAlab 3000 system (USA) with an 8-port selection valve and 10 ml syringe were used for sequential injection chromatographic separations in our study. The mobile phase used was acetonitrile-methanol-water (35:5:65, v/v/v) + 0.05% nonylamine, pH 2.5, flow rate 0.6 ml min(-1). The analysis time was <6 min. A novel sequential injection chromatography (SIC) technique with UV spectrophotometric detection was optimised and validated.
Robert F. Degenring - One of the best experts on this subject based on the ideXlab platform.
-
intravitreal Triamcinolone acetonide for treatment of intraocular proliferative exudative and neovascular diseases
Progress in Retinal and Eye Research, 2005Co-Authors: Jb Jonas, Ingrid Kreissig, Robert F. DegenringAbstract:Abstract Within the last three years, Triamcinolone acetonide has increasingly been applied intravitreally as treatment option for various intraocular neovascular edematous and proliferative disorders. The best response in terms of gain in visual acuity after the intravitreal injection of Triamcinolone acetonide was found in eyes with intraretinal edematous diseases such as diffuse diabetic macular edema, branch retinal vein occlusion, central retinal vein occlusion, and pseudophakic cystoid macular edema. Visual acuity increased and degree of intraocular inflammation decreased in eyes with various types of non-infectious uveitis including acute or chronic sympathetic ophthalmia and Adamantiadis–Behcet's disease. Intravitreal Triamcinolone may be useful as angiostatic therapy in eyes with iris neovascularization and proliferative ischemic retinopathies. Possibly, intravitreal Triamcinolone may be helpful as adjunct therapy for exudative age-related macular degeneration, possibly in combination with photodynamic therapy. In eyes with chronic, therapy resistant, ocular hypotony, intravitreal Triamcinolone can induce an increase in intraocular pressure and may stabilize the eye. The complications of intravitreal Triamcinolone therapy include secondary ocular hypertension in about 40% of the eyes injected, cataractogenesis, postoperative infectious and non-infectious endophthalmitis, and pseudo-endophthalmitis. Intravitreal Triamcinolone injection can be combined with other intraocular surgeries including cataract surgery. Cataract surgery performed some months after the injection does not show a markedly elevated rate of complications. If vision increases and eventually decreases again after an intravitreal Triamcinolone acetonide injection, the injection can be repeated. The duration of the effect of a single intravitreal injection of Triamcinolone depended on the dosage given. Given in a dosage of about 20 mg to non-vitrectomized eyes, the duration of the effect and of the side-effects was 6–9 months. Intravitreal Triamcinolone acetonide may offer a possibility for adjunctive treatment of intraocular edematous and neovascular disorders. One has to take into account the side-effects and the lack of long-term follow-up observations.
-
intraocular pressure elevation after intravitreal Triamcinolone acetonide injection
Ophthalmology, 2005Co-Authors: Jost B. Jonas, Ingrid Kreissig, Robert F. Degenring, Imren Akkoyun, Bernd A KamppeterAbstract:Purpose To report on intraocular pressure (IOP) after intravitreal injections of Triamcinolone acetonide. Design Meta-analysis of previously reported data and case series studies. Participants The study included 272 patients (305 eyes) receiving an intravitreal injection of approximately 20 mg Triamcinolone acetonide as treatment for diffuse diabetic macular edema (n = 84 patients), exudative age-related macular degeneration (n = 181 patients), retinal vein occlusions (n = 20 patients), uveitis (n = 9), pseudophakic cystoid macular edema (n = 6), and other reasons (n = 5). Mean follow-up was 10.4±6.7 months (median, 7.9 months; range, 3.0–35.7 months). Intervention Intravitreal injection of approximately 20 mg Triamcinolone acetonide. Main Outcome Measure Intraocular pressure. Results Intraocular pressure readings higher than 21 mmHg, 30 mmHg, 35 mmHg, and 40 mmHg, respectively, were measured in 112 (41.2%) patients, 31 (11.4%) patients, 15 (5.5%) patients, and 5 (1.8%) patients, respectively. Triamcinolone-induced IOP elevation was treated by antiglaucoma medication in all but 3 (1.0%) eyes, for which filtering surgery was performed. Mean IOP started to rise 1 week after injection and returned to baseline values approximately 8 to 9 months after injection. Younger age ( P = 0.029) was significantly associated with Triamcinolone-induced ocular hypertension. Triamcinolone responders and Triamcinolone nonresponders did not vary significantly in gender ( P = 0.42), refractive error ( P = 0.86), diabetes mellitus status ( P = 0.74), and reason for treatment. Conclusions These findings may be useful for comparing risks and benefits of intravitreal Triamcinolone acetonide therapy.
-
Cataract surgery combined with intravitreal injection of Triamcinolone acetonide.
European journal of ophthalmology, 2005Co-Authors: Jb Jonas, Ingrid Kreissig, Wido M. Budde, Robert F. DegenringAbstract:Purpose To evaluate whether the addition of cataract surgery to an intravitreal injection of Triamcinolone acetonide markedly increases frequency and spectrum of complications. Methods The comparative nonrandomized clinical interventional investigation included a study group of 60 eyes (56 patients) undergoing cataract surgery and additionally receiving an intravitreal injection of about 20 mg of Triamcinolone acetonide and a Triamcinolone control group of 290 eyes (262 patients) that consecutively received an intravitreal injection of about 20 mg Triamcinolone acetonide without cataract surgery. Reasons for intravitreal injection of Triamcinolone acetonide were exudative age-related macular degeneration (n=228; 65%), diffuse diabetic macular edema (n=94; 27%), central retinal vein occlusion (n=17; 5%), and branch retinal vein occlusion (n=11; 3%). Mean follow-up was 8.6+/-6.8 months. A second control group included 1068 patients (1068 eyes) who consecutively underwent routine cataract surgery without intravitreal injection. Results Study group and Triamcinolone control group did not vary significantly in best visual acuity during follow-up (p=0.08), final visual acuity at the end of follow-up (p=0.30), maximal intraocular pressure during follow-up (p=0.99), frequency of an intraocular pressure higher than 21 mmHg (p=0.66), and intraocular pressure at the end of follow-up (p=0.06). Postoperative infectious endophthalmitis, wound leakage or other corneal wound healing problems, persisting corneal endothelial decompensation, rhegmatogenous retinal detachment, marked postoperative pain, or a clinically significant decentration of the intraocular lens were not observed. Study group and the non-Triamcinolone control group did not vary significantly in the rate of posterior lens capsule rupture (p=0.11), postoperative infectious endophthalmitis, and persisting postoperative corneal endothelial decompensation. Conclusions The addition of cataract surgery to an intravitreal injection of Triamcinolone acetonide may not markedly increase amount and frequency of side effects and complications of intravitreal Triamcinolone acetonide. No safe conclusions can be reached regarding differences in frequency of postoperative infectious endophthalmitis.
-
Intravitreales Triamcinolonacetonid zur Behandlung intraokulärer ödematöser und neovaskulärer Erkrankungen
Der Ophthalmologe, 2004Co-Authors: Jb Jonas, Ingrid Kreissig, B. Kamppeter, Robert F. DegenringAbstract:Background Within the last 2 years, intravitreal application of Triamcinolone acetonide has exponentially increased as a treatment option for various intraocular neovascular and edematous proliferative disorders. Methods and results The best response to intravitreal Triamcinolone acetonide injection in terms of gain in visual acuity was obtained for eyes with intraretinal edematous diseases such as diffuse diabetic macular edema, branch retinal vein occlusion, central retinal vein occlusion, and pseudophakic cystoid macular edema. Visual acuity increased and degree of intraocular inflammation decreased in eyes with various types of noninfectious uveitis including sympathetic ophthalmia. Intravitreal Triamcinolone may be useful as angiostatic therapy in eyes with iris neovascularization and proliferative ischemic retinopathies. Possibly, intravitreal Triamcinolone may be helpful for exudative age-related macular degeneration, alone or in combination with photodynamic therapy. In eyes with chronic, therapy-resistant, ocular hypotony, intravitreal Triamcinolone can induce an increase in intraocular pressure and may stabilize the eye. The complications of intravitreal Triamcinolone therapy, such as secondary ocular hypertension in about 40% of the eyes injected, cataractogenesis, postoperative infectious and noninfectious endophthalmitis, and pseudo-endophthalmitis will be covered in another article. Intravitreal Triamcinolone injection can be combined with other intraocular surgeries including cataract surgery. Cataract surgery performed some months after the injection did not show a markedly elevated rate of complications. If vision increases after the intravitreal Triamcinolone injection, the injection can be repeated. The duration of the effect of a single intravitreal injection of Triamcinolone ranges between 2 and 9 months, probably depending on the dosage used. Conclusions Intravitreal Triamcinolone acetonide may offer a possibility for adjunctive treatment of intraocular oedematous and neovascular disorders. One has to take into account the side effects and the lack of long-term follow-up observations. Hintergrund Intravitreales Triamcinolonacetonid ist in den letzten beiden Jahren exponentiell zunehmend zur Behandlung verschiedener intraokulärer ödematöser und neovaskulärer Erkrankungen verwendet worden. Ziel dieser Arbeit ist es, einen Überblick über die bisher vorliegenden Ergebnisse zu geben. Methode und Ergebnisse Die relativ besten Therapieergebnisse wurden bisher bei intraretinalen ödematösen Erkrankungen erreicht, insbesondere beim diffusen diabetischen Makulaödem und bei zystoiden Makulaödemen durch retinalen Zentralvenen- und Venenastverschluss. Zusätzlich liegen positive Berichte über die Verwendung von intravitrealem Triamcinolonacetonid zur Therapie der sympathischen Ophthalmie, perifovealer Teleangieaktasien und nichtinfektiöser Uveitis unterschiedlicher Genese vor. Möglicherweise ist intravitreales Triamcinolonacetonid hilfreich bei der angiostatischen Therapie der Rubeosis iridis und bei proliferierenden ischämischen Retinopathien. Eventuell hat es, mit oder ohne photodynamische Therapie, zusätzlich ein gewisses Einsatzgebiet bei der exsudativen altersassoziierten Makuladegeneration. Bei chronischer, therapieresistenter, okulärer Hypotonie am Übergang zur Phthisis bulbi kann manchmal durch eine intravitreale Injektion von Triamcinolon eine Steigerung des Augeninnendrucks und eine Stabilisierung der inneren Homoiostase des Auges erreicht werden. Die Rolle von intravitrealem Triamcinolon zur unterstützenden Therapie einer proliferativen Vitreoretinopathie ist unklar. Die Injektion kann mit einer Kataraktoperation kombiniert werden. Kataraktoperationen, die Monate nach der Injektion durchgeführt werden, haben keine wesentlich erhöhte Komplikationsrate. Erfolgt auf eine erste intravitreale Injektion ein Visusanstieg, kann sie wiederholt werden. Die Dauer der Wirkung einer intravitrealen Triamcinoloninjektion liegt wahrscheinlich in Abhängigkeit von der verwendeten Dosis zwischen 2 und 9 Monaten. Triamcinolon wurde bis zu 9 Monate nach einer Injektion von 25 mg im Kammerwasser nachgewiesen. Komplikationen der intravitrealen Applikation von Triamcinolonacetonid, wie z. B. eine okuläre Hypertension in etwa 40% der injizierten Augen, ein kataraktogener Effekt, eine postoperative infektiöse oder sterile Endophthalmitis und eine Pseudoendophthalmitis, werden in einer weiteren Arbeit dargestellt. Schlussfolgerungen Die intravitreale Triamcinolontherapie ist unter Umständen eine zusätzliche Möglichkeit, um intraokuläre ödematöse und neovaskuläre Erkrankungen zu behandeln. Die Komplikationen und die noch fehlenden Langzeitbeobachtungen sind zu bedenken.
-
Serum levels of Triamcinolone acetonide after intravitreal injection
American journal of ophthalmology, 2004Co-Authors: Robert F. Degenring, Jost B. JonasAbstract:Abstract Purpose To evaluate serum levels of Triamcinolone acetonide after intravitreal high-dose injection. Design Prospective, interventional case series study. Methods For 20 consecutive patients, venous blood samples were taken before and 13 ± 19 days (range 4 to 92) after an intravitreal injection of 20 to 25 mg Triamcinolone acetonide as treatment of edematous macular diseases. Results Serum levels of Triamcinolone acetonide did not differ significantly ( P = .174; t test for paired matches) preoperatively (0 μg/l) and postoperatively (0.065 μg/l ± 0.21 μg/l). In 18 eyes (90%), Triamcinolone acetonide could not be detected in serum samples. For two patients (10%), serum samples taken 5 days and 7 days after the injection, respectively, contained 0.5 μg/l Triamcinolone acetonide and 0.8 μg/l Triamcinolone acetonide, respectively. Conclusion After an intravitreal high-dose injection of 20 to 25 mg Triamcinolone acetonide, Triamcinolone acetonide is not, or only marginally, detectable in serum samples obtained within 4 to 92 days after the injection.
Petr Solich - One of the best experts on this subject based on the ideXlab platform.
-
advantages of application of uplc in pharmaceutical analysis
Talanta, 2006Co-Authors: Lucie Nováková, Ludmila Matysová, Petr SolichAbstract:Ultra Performance Liquid Chromatography (UPLC) is a relatively new technique giving new possibilities in liquid chromatography, especially concerning decrease of time and solvent consumption. UPLC chromatographic system is designed in a special way to withstand high system back-pressures. Special analytical columns UPLC Acquity UPLC BEH C(18) packed with 1.7 microm particles are used in connection with this system. The quality control analyses of four pharmaceutical formulations were transferred from HPLC to UPLC system. The results are compared for Triamcinolon cream containing trimacinolone acetonide, methylparaben, propylparaben and Triamcinolone as degradation product, for Hydrocortison cream (hydrocortisone acetate, methylparaben, propylparaben and hydrocortisone degradation product), for Indomethacin gel (indomethacin and its degradation products 4-chlorobenzoic acid and 5-methoxy-2-methylindoleacetic acid) and for Estrogel gel (estradiol, methylparaben, propylparaben and estrone as degradation product). The UPLC system allows shortening analysis time up to nine times comparing to the conventional system using 5 microm particle packed analytical columns. In comparison with 3 microm particle packed analytical columns analysis should be shortened about three times. The negative effect of particle decrease is back-pressure increase about nine times (versus 5 microm) or three times (versus 3 microm), respectively. The separation on UPLC is performed under very high pressures (up to 100MPa is possible in UPLC system), but it has no negative influence on analytical column or other components of chromatographic system. Separation efficiency remains maintained or is even improved. Differences and SST parameters, advantages and disadvantages of UPLC are discussed.
-
reversed phase porous silica rods an alternative approach to high performance liquid chromatographic separation using the sequential injection chromatography technique
Journal of Chromatography A, 2003Co-Authors: Dalibor Satinský, Petr Solich, Jitka Huclova, Rolf KarlicekAbstract:Abstract A commercially available porous silica rod column was used as a separation tool for the sequential injection analysis (SIA). A porous solid monolithic column showed high performance at a low pressure, allowing sequential injection analysis to be used for the first time for separation in HPLC fashion. In this contribution, we tried to demonstrate a new separation concept with SIA manifold for the simultaneous determination of four different compounds (methylparaben (MP), propylparaben (PP), Triamcinolone acetonide (TCA) and internal standard ketoprofen (KP)) in a pharmaceutical triamcinolon cream 0.1% formulation. A Chromolith Flash RP-18e, 25 mm ×4.6 mm column with a 10 mm pre-column (Merck, Germany) and a FIAlab 3000 system (USA) with an 8-port selection valve and 10 ml syringe were used for sequential injection chromatographic separations in our study. The mobile phase used was acetonitrile–methanol–water (35:5:65, v/v/v) + 0.05% nonylamine, pH 2.5, flow rate 0.6 ml min−1. The analysis time was
-
reversed phase porous silica rods an alternative approach to high performance liquid chromatographic separation using the sequential injection chromatography technique
Journal of Chromatography A, 2003Co-Authors: Dalibor Satinský, Petr Solich, Jitka Huclova, Rolf KarlicekAbstract:A commercially available porous silica rod column was used as a separation tool for the sequential injection analysis (SIA). A porous solid monolithic column showed high performance at a low pressure, allowing sequential injection analysis to be used for the first time for separation in HPLC fashion. In this contribution, we tried to demonstrate a new separation concept with SIA manifold for the simultaneous determination of four different compounds (methylparaben (MP), propylparaben (PP), Triamcinolone acetonide (TCA) and internal standard ketoprofen (KP)) in a pharmaceutical triamcinolon cream 0.1% formulation. A Chromolith Flash RP-18e, 25 mm x 4.6 mm column with a 10 mm pre-column (Merck, Germany) and a FIAlab 3000 system (USA) with an 8-port selection valve and 10 ml syringe were used for sequential injection chromatographic separations in our study. The mobile phase used was acetonitrile-methanol-water (35:5:65, v/v/v) + 0.05% nonylamine, pH 2.5, flow rate 0.6 ml min(-1). The analysis time was <6 min. A novel sequential injection chromatography (SIC) technique with UV spectrophotometric detection was optimised and validated.
Dalibor Satinský - One of the best experts on this subject based on the ideXlab platform.
-
reversed phase porous silica rods an alternative approach to high performance liquid chromatographic separation using the sequential injection chromatography technique
Journal of Chromatography A, 2003Co-Authors: Dalibor Satinský, Petr Solich, Jitka Huclova, Rolf KarlicekAbstract:Abstract A commercially available porous silica rod column was used as a separation tool for the sequential injection analysis (SIA). A porous solid monolithic column showed high performance at a low pressure, allowing sequential injection analysis to be used for the first time for separation in HPLC fashion. In this contribution, we tried to demonstrate a new separation concept with SIA manifold for the simultaneous determination of four different compounds (methylparaben (MP), propylparaben (PP), Triamcinolone acetonide (TCA) and internal standard ketoprofen (KP)) in a pharmaceutical triamcinolon cream 0.1% formulation. A Chromolith Flash RP-18e, 25 mm ×4.6 mm column with a 10 mm pre-column (Merck, Germany) and a FIAlab 3000 system (USA) with an 8-port selection valve and 10 ml syringe were used for sequential injection chromatographic separations in our study. The mobile phase used was acetonitrile–methanol–water (35:5:65, v/v/v) + 0.05% nonylamine, pH 2.5, flow rate 0.6 ml min−1. The analysis time was
-
reversed phase porous silica rods an alternative approach to high performance liquid chromatographic separation using the sequential injection chromatography technique
Journal of Chromatography A, 2003Co-Authors: Dalibor Satinský, Petr Solich, Jitka Huclova, Rolf KarlicekAbstract:A commercially available porous silica rod column was used as a separation tool for the sequential injection analysis (SIA). A porous solid monolithic column showed high performance at a low pressure, allowing sequential injection analysis to be used for the first time for separation in HPLC fashion. In this contribution, we tried to demonstrate a new separation concept with SIA manifold for the simultaneous determination of four different compounds (methylparaben (MP), propylparaben (PP), Triamcinolone acetonide (TCA) and internal standard ketoprofen (KP)) in a pharmaceutical triamcinolon cream 0.1% formulation. A Chromolith Flash RP-18e, 25 mm x 4.6 mm column with a 10 mm pre-column (Merck, Germany) and a FIAlab 3000 system (USA) with an 8-port selection valve and 10 ml syringe were used for sequential injection chromatographic separations in our study. The mobile phase used was acetonitrile-methanol-water (35:5:65, v/v/v) + 0.05% nonylamine, pH 2.5, flow rate 0.6 ml min(-1). The analysis time was <6 min. A novel sequential injection chromatography (SIC) technique with UV spectrophotometric detection was optimised and validated.
